Development, characterization and pharmacological evaluation of amino acid prodrugs of (+)-Ibuprofen

Nija B1, Arun Rasheed1, Kottaimuthu A2

1Department of pharmaceutical chemistry, Al Shifa College of pharmacy, Perinthalmanna, Malappuram District, Kerala, India
2Department of pharmacy, Annamalai University, Annamalai Nagar-608 002, Tamilnadu, India

ABSTRACT

The current research work investigate the neuronal pathway associated with NSAIDs that lead to the reduction in the initiation and progression of neurodegenerative diseases such as Alzheimer’s disease, Parkinsonism etc. This research was developed amino acid prodrugs of the active enantiomer of ibuprofen, (+)-IBN and checks the pharmacological effects, neuroprotective effect, anti inflammatory effect and anti-ulcerogenic effect. The treatment using (+)-IBN reduced the action of micoglia and the release of cytokine especially TNFα that are mainly involved in the neurodegenerative process. (+)-IBN reduced the deposition of soluble beta amyloid plaque by inhibiting the amyloid precursor protein, beta-secretase 1 and also enhancing the degradation process of beta amyloid via induction of insulin degrading enzyme. (+)-IBN also showed the property that the reduction in the TAU misfolding process. Therefore, the synthesized (+)-IBN amino acid prodrugs treatment effectively produce neuroprotective action, both restoring memory related risk factors and reversing multiple brain neuropathological hallmarks. The current research study developed the three amino acid prodrugs of (+)-ibuprofen by conjugating with L-phenyl alanine, L-tryptophan and L-tyrosine also the physico-chemical characterization and spectral characterization was done. This study modify the carboxylic acid functional group present in the NSAIDs that lead to the formation of prodrugs with enhanced anti-inflammatory activity, reduced side effects and protective effect against neurodegenerative processes.

INTRODUCTION

The general pharmacological activities of Non-steroidal anti-inflammatory drugs (NSAIDs) are analgesic activity, antipyretic activity and anti-inflammatory activity. The general mechanism of NSAIDs is explained through the inhibition of prostaglandins(PGs) by the action of two cyclooxygenase enzymes. PGs having significant role in various cellular activities like gastrointestinal protection, inflammation, angiogenesis, hemostasis etc. (Gunaydin and Bilge, 2018). Many studies have been conducted for investigating the different pharmacological and therapeutical activities of NSAIDs. Studies revealed the significance of NSAIDs in various activities and treatment strategies like...
Table 1: Physicochemical characterization of drug and synthesized prodrugs

| Prodrug | Molecular weight | Colour | LogP | Protein binding value (%) | Melting point (°C) | Yield (%) | RF value | Elemental analysis |
|---------|-----------------|--------|------|---------------------------|-------------------|-----------|----------|-------------------|
| (+)-IBN 1 | 406 | Off white | 1.23 | 74 | 68 - 69 | 74 | 0.56 | C 73.86 | H 7.44 | N 6.89 |
| (+)-IBN 2 | 367 | Off white | 1.17 | 68 | 58 - 59 | 78 | 0.64 | C 75.15 | H 7.95 | N 3.81 |
| (+)-IBN 3 | 383 | Yellowish white | 1.16 | 58 | 56 - 58 | 70 | 0.67 | C 72.04 | H 7.62 | N 3.65 |

*ethyl acetate : n-hexane 1:2

Table 2: ADME prediction of synthesized prodrugs

| Compound ID | QPlogPo/w | QPPCaco | QPlogS | QPPMDCK | % Absorption |
|-------------|-----------|---------|--------|---------|--------------|
| (+)-IBN 1   | 5.21      | 1358.18 | -5.95  | 950.47  | 100          |
| (+)-IBN 2   | 4.68      | 1591.08 | 5.014  | 1105.55 | 100          |
| (+)-IBN 3   | 4.67      | 609.32  | -6.488 | 367.94  | 100          |
| (+)-IBN     | 3.49      | 337.89  | -3.755 | 194.74  | 92.67        |

Table 3: Brain targeting efficiency of (+)-IBN and its prodrugs

| Drug       | C_{Plasma} (μg/ml) | C_{brain} (μg/ml) | BTE |
|------------|---------------------|-------------------|-----|
| (+)-IBN    | 19.72 ± 0.016       | 1.12 ± 0.018      | 0.057 ± 0.016 |
| (+)-IBN 1  | 18.02 ± 0.021       | 7.91 ± 0.025      | 0.439 ± 0.023 |
| (+)-IBN 2  | 16.15 ± 0.029       | 8.64 ± 0.032      | 0.535 ± 0.030 |
| (+)-IBN 3  | 15.48 ± 0.019       | 4.32 ± 0.021      | 0.279 ± 0.020 |

Value expressed as mean±SEM of five experiments. Statistical significance by ANOVA followed by Dunnet’s test, a p<0.01 vs (+)-IBN.

Table 4: Time – Concentration profile and BTE of (+)-IBN and (+)-IBN 2

| Time (min) | Concentration (μg/mL) in Plasma | Concentration (μg/mL) in Brain | Brain targeting efficiency |
|------------|---------------------------------|-------------------------------|---------------------------|
| 10         | (+)-IBN 19.72 ± 0.016           | (+)-IBN 1.12 ± 0.018          | 0.057 ± 0.016             |
| 20         | (+)-IBN 17.22 ± 0.021           | (+)-IBN 2.088 ± 0.024         | 0.0512 ± 0.019            |
| 30         | (+)-IBN 12.19 ± 0.013           | (+)-IBN 3.47 ± 0.024          | 0.0443 ± 0.033            |
| 60         | (+)-IBN 7.82 ± 0.031            | (+)-IBN 2.023 ± 0.036         | 0.0285 ± 0.028            |
| 120        | (+)-IBN 5.12 ± 0.026            | (+)-IBN 0.117 ± 0.028         | 0.0229 ± 0.018            |
| 240        | (+)-IBN 2.28 ± 0.029            | (+)-IBN 0.04 ± 0.033          | 0.01750 ± 0.030           |

Value expressed as mean±SEM of five experiments. Statistical significance by ANOVA followed by Dunnet’s test, a p<0.001 b p<0.01 vs (+)-IBN.
Table 5: Brain targeting efficiency parameters

| Parameters                        | Brain |
|-----------------------------------|-------|
| Relative Uptake Efficiency (RE)   | 9.21  |
| Concentration Efficiency (CE)     | 7.71  |
| Drug Targeting Index (DTI)        | 17.93 |

Table 6: Anti Inflammatory Activity

| Group | Prodrug   | Anti-inflammatory activity |
|-------|-----------|---------------------------|
|       | 0.5 hour  | 1 hour | 2 hour | 4 hour | 6 hour |
| I     | Normal    | -      | -      | -      | -      |
| II    | (+)-IBN   | 48±1.1 | 62.0 ± 1.2 | 60.6 ± 2.1 | 56.1 ± 1.2 | 43.3 ± 1.5 |
| III   | (+)-IBN 1 | 42.0 ± 1.2<sup>d</sup> | 50.1 ± 1.0<sup>d</sup> | 59.0 ± 1.3<sup>d</sup> | 71.7±1.1<sup>d</sup> | 73.4±1.2<sup>d</sup> |
| IV    | (+)-IBN 2 | 45±1.1<sup>d</sup> | 62.5 ± 1.7<sup>d</sup> | 67.4±1.1<sup>d</sup> | 71.7 ± 1.1<sup>d</sup> | 77.3 ± 2.2<sup>d</sup> |
| V     | (+)-IBN 3 | 42.0 ± 1.5<sup>d</sup> | 50.1 ± 1.8<sup>d</sup> | 54.4±1.7<sup>d</sup> | 58.3±1.0<sup>d</sup> | 64.5±1.3<sup>d</sup> |

Values were the mean ± SD of six observations. <sup>d</sup>P <0.05, done by ANOVA followed by Dunnett’s test. Comparison between group II vs III, IV and V.

Figure 1: Scheme for the synthesis of (+)-IBN 1, (+)-IBN 2 and (+)-IBN 3
anticancer activity, anti-Alzheimer’s activity, anti-parkinsonian activity etc. (Osafo and Agyare, 2017; Rebecca and Wong, 2019; Etcheto et al., 2017; Ajmone-Cat et al., 2010).

The current research aims to develop the novel amino acid prodrugs of NSAID, (+)-IBN and investigate the effect of NSAIDs and their conjugates in different areas. The use of prodrugs based approach modify the carboxylic acid functional group of NSAIDs that produced the compounds with better physical-chemical properties, pharmacokinetic-pharmacodynamic properties, pharmacological activities and reduced toxicity profile (Rasheed et al., 2011; P et al., 2018).

Literature survey showed that the long term use of NSAIDs reduce the risk and progression of neuro-degeneration by the significant effect on the microglial activity, reduction in beta amyloid production, facilitate the Aβ degradation, reduction in the process of TAU protein hyperphosphorylation and reduced the problems like spatial learning and memory impairment (Khansari and Halliwell, 2019; Španić et al., 2019). So this study synthesize the three amino acid prodrugs and expect to give improved properties (Rasheed and Kumar, 2008).

MATERIALS AND METHODS

Reagent and chemicals

The amino acids were obtained from Hi-media chemicals, India, (+)-IBN was obtained from Alkem laboratories, Mumbai and all other reagents are analytical grade. The melting points were monitored by the Melting point apparatus and the elemental analysis was done in CDRI, Lucknow. The infra red spectra were recorded by IR spectrometer, Al Shifa College of pharmacy. 1H NMR, 13C NMR and Mass spectra were recorded in IICB, Kolkata. The homogenate was prepared by using the homogeniser, Remi instruments division. The histopathological studies were carried out in Department of Pathology, KIMS Al-shifa hospital Kerala. The cell line studies of neurodegenerative disease were carried out in Biogenix, Trivandrum.

Experimental procedures

Synthesis

This research study synthesize the three novel prodrugs of (+)-IBN by Schotten-Baumann method in which the drug was conjugated with aminoacids like L-tryptophan(a), L-phenyl alanine(b) and L-tyrosine(c) produced (+)-IBN-1, (+)-IBN-2 and (+)-IBN-3 shown in Figure 1 as per the literature (Rasheed et al., 2011).

(+)-IBN1 (S(+)-methyl-3-(1H-indol-3-yl)-2-(2-(4-isobutyl phenyl)propanamido)propanoate)

FTIR(cm⁻¹)3400(NH-amide), 3007(aromatic-CH), 1581, 1660(CO-ester), 1453(CN), 1228, 1350(CO of ester); 1H NMR(δ, ppm)(D₂O): 1.37(J=7.1Hz, 3H), 1.79(J=6.8Hz, 1H), 3.58(J=7.1Hz, 2H), 7.19(5H, indole ring), 8.28(1H,NH), 8.22 (1H,NH), 7.2(4H,benzene ring), 13C NMR(δ, ppm) (D₂O): 18.40, 21.56, 29.68, 44.15, 48.14, 112.71, 115.88,
Figure 5: BTE of the (+)-IBN and (+)-IBN 2

Figure 6: Open field exploration

Figure 7: Marble burying test

Figure 8: Water maze test

Figure 9: Antioxidant activity

116.98, 128.28, 129.21, 129.56, 133.68, 134.46, 134.68, 147.02, 171.87, 184; Mass (m/z): 406 (M+).

(+)-IBN2 (S(+)methyl2-(2-(4-isobutylphenyl)propanamido)-3-phenylpropanoate)

FTIR (cm−1) 3346 (NH- amide), 2955, 2921 (aromatic-CH), 1547 (COester), 1406 (CN), 1288 (COester); 1H NMR (δ, ppm) (D2O): 1.37 (J=7.1Hz, 3H), 3.61 (J=7.2Hz, 1H), 7.26 (4H, benzenering), 8.52 (1H, NH), 7.40 (J=6.6Hz, 1H), 7.25 (4H, benzenering), 13C NMR (δ, ppm) (D2O): 18.41, 21.47, 29.68, 44.15, 48.14, 120.88, 122.02, 122.45, 123.95, 134.46, 127.28, 129.91, 130.62, 131.17, 133.16, 138.08, 147.42, 147.64, 157.02, 171.07, 184; Mass (m/z): 367 (M+).

(+)-IBN3 (S(+)methyl3-(4-hydroxyphenyl)2-(2-(4-isobutylphenyl)propanamido)-3-phenylpropanoate); FTIR (cm−1) 3340
physical-chemical characterization methods
The progression of the reaction and the purity of the compounds confirmed by thin layer chromatography on pre-coated silica-G plates and the detection method is UV chamber visualization (Rao and Shil, 2019; Kemp, 1991). The melting point of the drug and prodrugs were done for confirming the product formation and it was done by using melting point apparatus (John and Young, 2013). Solubility of the drug and amide prodrugs were done in different solvents to identify the nature of the compounds (Qiu et al., 2009). The quantification of the elements present in the synthesized compounds and it was compared with that of the calculate values are significant method to confirm the successful synthesis (Margui and Grieken, 2014). The partition coefficient of the prodrugs were done by shake falsk method explained by (Paschke et al., 2004). Protein binding of the drugs and prodrugs were to confirm that the drug is available for the pharmacological activity and it was done by equilibrium dialysis method explained by (Pinger et al., 2017; Barton et al., 2007). Spectral characterization was very much important to confirm the desired structures and done by IR, $^1$H NMR, $^{13}$C NMR and Mass spectroscopy (Silverstein and Webster, 1998; Jürgen, 2004).

in silico Studies
ADME Optimization is significant in the drug development process that was done by QikProp according to the Schrödinger [Internet], USA (Schrödinger, 2015).

Biodistribution and pharmacokinetic studies
The best distributed prodrug in the brain can be found out by bio-distribution study and that can be monitored by the parameter brain targeting efficiency. The procedure was according to the (Zhang et al., 2012).

Pharmacological evaluation
The activities tested were anti-inflammatory activity, ulcerogenecity and protective effect in brain. In brain, (+)-IBN and its synthesized prodrugs were evaluated for behavioral parameters, antioxidant parameter, histopathology of the brain cortex and the results were compared with that of the parent drug. Neurotoxicity was induced by aluminium induced model by the oral administration of aluminium chloride [100 mg/kg/day] for three months (Shati et al., 2011). The animals were grouped in to six groups and each group contained six animals. The first group acts as control that receives normal saline. The second group received aluminium chloride only. The third, fourth, fifth, sixth group received (+)-IBN [1.39 mg], (+)-IBN 1 [2.75 mg], (+)-IBN 2 [1.6 mg] and (+)-IBN 3 [2.0 mg] respectively by oral administration. The animal experiment was performed as per the guide lines of the animal ethical committee (Reg. No: 1195/PO/Re/S/08/CPCEA) Al Shifa College of Pharmacy, Kerala, India.

Behavioral studies
Open field tests
The open field exploration study was carry out according to the procedure explained by (Tair et al., 2016)

Marble burying test
The marble burying test was done by (Angoa-Pérez et al., 2013; Wolmarans et al., 2016).

Water maze task
This test access the spatial learning and memory conducted as per the procedure followed by (Vorhees and Williams, 2006; Nunez, 2008).

Biochemical estimations
Antioxidant parameters were estimated by testing the activity of the enzyme catalase and superoxide dismutase (SOD) (Pham-Huy et al., 2008). SOD activity was done by the procedure explained by (Weydert and Cullen, 2010) and the catalase activity was done as per the procedure (Goth, 1991; Hadwan and Abed, 2016).

Histopathological Studies
The cortex of the brain was collected and histopathologically evaluated by using haematoxylin-eosin dye in Department of pathology, KIMS-Al Shifa hospital, kerala and The sections were examined microscopically for histopathological changes observed and compare with that of parent NSAID (Nobakht et al., 2011).

Cell Line study- invitro neuroprotective effect determination by MTT assay
Cell line was conducted by the MTT assay and percentage viability was found out at different concentrations. (Martinez et al., 2020)
Anti-inflammatory activity and ulcerogenicity study

Anti-inflammatory activity was performed by carrageenan induced paw edema method explained by (Khedir et al., 2016). The main side effect of the NSAIDs is the production of ulcers that were studied and monitored as per the procedure by (Rasheed et al., 2016).

Statistical analysis

Statistical significance was done by ANOVA and the values were expressed as mean ± SD.

RESULTS AND DISCUSSION

Physical and chemical characterization methods

The nature of the prodrugs was evaluated by various methods. Different methods adopted and their results were given in the Table 1. The data in the table revealed that the formation of pure amide prodrugs. The melting point determination and thin layer chromatography results showed the formation of the products. The solubility studies proved the organic solubility of the prodrugs that showed its
lipophilic nature. Also the Log P value calculated from the partition coefficient method revealed the enhancement of lipophilic profile of the amide prodrugs. The lower protein binding values indicate the availability of the drug in various biological fluids. Elemental analysis data provided the comparable values with the theoretical values spectral data confirm the structure of the compounds with amide and ester linkages.

**Insilico studies**

The ADME optimization is very much significant and that was done by insilico tool. Data was given in Table ??.

In Table ?? shows, a Predicted octanol/water partition co-efficient log p (acceptable range: −2.0 to 6.5). b Predicted Caco-2 cell permeability in nm/s (acceptable range, <25 is poor and >500 is great). c Predicted aqueous solubility; S in mol/L (acceptable range: −6.5 to 0.5). d Predicted apparent MDCK cell permeability for the blood-brain barrier, (acceptable range, < 25 is poor and >500 is great) e Percentage of human oral absorption (< 25% is poor and >80% is high).

**Biodistribution and Pharmacokinetics**

The drug with more distribution in the brain and Brain targeting efficiency (BTE) can be found out from the biodistribution study and the data was presented in Table 3 and graphically represented in Figures 2 and 3. (+)-IBN 2 showed higher BTE value and brain distribution shown in Figure 3. So Pharmacokinetic studies were carried out using (+)-IBN and (+)-IBN 2. The concentration-time profile of plasma and brain and BTE was given in Table 4 graphically represented in Figures 4 and 5 respectively. The targeting efficiency parameters are presented in Table 5. The study revealed that the concentration of the prodrug after 10 minutes of administration is very high in brain compared to that of (+)-IBN. The brain targeting efficiency of the prodrugs were high compared to that of (+)-IBN. Also, the RE,CE and DTI showed the remarkable high distribution of (+)-IBN 2 compared to that of (+)-IBN.

**Pharmacological Evaluation**

Behavioral parameters were monitored by Open field test [Figure 6], Marble burying test [Figure 7], and Water maze test [Figure 8]. In open field test, head dipping, rearing and line crossing were considered for monitoring the cognitive activity. Behavioral data obtained from the marble burying test is a parameter to test the locomotion. The behavioral studies proved that the enhancement in the locomotion, memory, spatial learning etc shown by the prodrugs compared to that of the parent NSAID that indicates that the potential activity of (+)-IBN is nil due to the inability to cross BBB.

**Biochemical Estimation**

The evaluation of antioxidant parameters indicated the protective effect of the synthesized amide prodrugs against neurodegeneration. SOD and Catalase activity were graphically represented in Figure 9.

**Histopathological analysis**

The histopathology study of the brain cortex was taken and concluded that the prodrug treated group, all the three different aminoacid prodrugs shown the normal architecture of the cells without any spongiform cells. The study proved the protective nature of the NSAIDs shown in Figure 10.

**In vitro neuroprotective effect determination by MTT assay**

From the cell line studies, the effects of the samples (+)-IBN-2 on H2O2 induced cell death was examined in SH-SY5Y cells. As illustrated in the Figure 11 at a concentration of 25 μg.mL−1 all two samples are having a neuroprotective activity by measuring the percentage viability.

**Anti Inflammatory Activity**

The percentage anti inflammatory activity of (+)-IBN and its prodrugs were determined and are given in Table 6. A graphical representation was shown in Figure 12. From the study concluded that the synergistic activity profile of the synthesized amide prodrugs with the significance of < 0.05. After the six hours observations the amide prodrugs showed about 70 percentage of anti inflammatory activity that is very high compared to that of the parent (+)-IBN.

**Ulcerogenic Activity**

The ulcer formation was monitored and quantitatively represented in ulcer index shown in Figure 13.
CONCLUSIONS

This research study proved that the new amide prodrugs showed better physico chemical properties, transport properties, bio-distribution and pharmacological activities. On the basis of the results, it can be concluded that prodrug approach could successfully attain the goal of improving the transport properties through the BBB and protective effect against the degeneration in brain. The prodrug approach on the NSAIDs provides the improvement in the anti inflammatory activity, reduction in the gastric toxicity and behavioral test, antioxidant parameters revealed the protective effect in the brain. The study revealed that the new synthesized prodrugs showed better lipophilicity, brain targeting efficiency, drug targeting index, relative efficiency and concentration efficiency, anti inflammatory activity and anti ulcerogenecity than the parent drug. On the basis of the results, concluded that the prodrug based drug design lead to the formation of the products with the enhancement of the properties.

Funding Support

None.

Conflict of Interest

None.

REFERENCES

Ajmone-Cat, M. A., Bernardo, A., Greco, A., Minghetti, L. 2010. Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions. *Pharmaceuticals*, 3(6):1949–1965.

Angoa-Pérez, M., Kane, M. J., Briggs, D. I., Francescutti, D. M., Kuhn, D. M. 2013. Marble Burying and Nestlet Shredding as Tests of Repetitive, Compulsive-like Behaviors in Mice. *Journal of Visualized Experiments*, (82):50978–50978.

Barton, P., Austin, R. P., Fessey, R. E. 2007. Vitro Models for Plasma Binding and Tissue Storage. 5:321–340.

Etcheto, M., Sánchez-López, E., Pons, L., Busquets, O., Olloquequi, J., Beas-Zarate, C., Pallas, M., García, M. L., Auladell, C., Folch, J., Camins, A. 2017. Dexametabolone prevents neurodegeneration and cognitive decline in APPswe / PS1dE9 through multiple signaling pathways. *Redox Biology*, 13:345–352.

Goth, L. 1991. A simple method for determination of serum catalase activity and revision of reference range. *Clinica chimica acta*, 196(2-3):143–151.

Gunaydin, C., Bilge, S. S. 2018. Effects of nonsteroidal anti-inflammatory drugs at the molecular level. *The Eurasian journal of medicine*, 50:116–116.

Hadwan, M. H., Abed, H. N. 2016. Data supporting the spectrophotometric method for the estimation of catalase activity. *Data in Brief*, 6:194–199.

John, O., Young, J. 2013. True Melting Point Determination. *Academia*, 18:203–208.

Jurgen, H. 2004. Gross Mass Spectrometry- A Textbook. pages 355–376, Berlin Heidelberg New York. Springer.

Kemp, W. 1991. Organic Spectroscopy. pages 1–416, London. MacMillan Press Ltd.

Khansari, P. S., Halliwell, R. F. 2019. Mechanisms Underlying Neuroprotection by the NSAID Mefenamic Acid in an Experimental Model of Stroke. *Frontiers in Neuroscience*, 13:64–64.

Khedir, S. B., Mzid, M., Bardaa, S., Moalla, D., Sahnoun, Z., Rebai, T. 2016. In vivo evaluation of the anti-inflammatory effect of *Pistacia lentiscus* fruit oil and its effects on oxidative stress.

Margui, E., Grienden, R. V. 2014. Overview of most commonly used analytical techniques for elemental analysis. pages 8–10.

Nobakht, M., Hoseini, S. M., Mortazavi, P., Sohrabi, I., Esmailzade, B., Roosh, N. R., Omidzahir, S. 2011. Neuropathological changes in brain cortex and hippocampus in a rat model of Alzheimer’s disease. *Iranian biomedical journal*, 15(1-2):51–51.

Nunez, J. 2008. Morris Water Maze Experiment. *Journal of Visualized Experiments*, (19):897–897.
Osafo, N., Agyare, C. 2017. Mechanism of Action of Nonsteroidal Anti-Inflammatory Drugs, Nonsteroidal Anti-Inflammatory Drugs. IntechOpen. Ali Gamal Ahmed Al-kaf.

P. J. P., A. L. R., MV. B. R. 2018. Design and Schematic Evaluation of Dextran Conjugated Dexibuprofen, a Gastrosparing NSAID. American Journal of Chemistry, 3(1):30–41.

Paschke, A., Neitzel, P. L., Walther, W., Schüürmann, G. 2004. Octanol/Water Partition Coefficient of Selected Herbicides: Determination Using Shake-Flask Method and Reversed-Phase High-Performance Liquid Chromatography. Journal of Chemical & Engineering Data, 49(6):1639–1642.

Pham-Huy, L. A., He, H., Pham-Huy, C. 2008. Free radicals, antioxidants in disease and health. International journal of biomedical science: IJBS, 4(2):89–89.

Pinger, C. W., Heller, A. A., Spence, D. M. 2017. A Printed Equilibrium Dialysis Device with Integrated Membranes for Improved Binding Affinity Measurements. Analytical Chemistry, 89(14):7302–7306.

Qiu, Y., Chen, Y., Liu, L., Geoff, G., Zhang, Z. 2009. Developing solid oral dosage forms: Pharmaceutical theory and practice. pages 1–943, USA. Academic Press.

Rao, M. R. K., Shil, S. 2019. Some Observations on Thin Layer Chromatography Technique. International Journal of Recent Technology and Engineering (IJRTE), 8(2):1700–1702.

Rasheed, A., Kumar, C. K. A. 2008. Novel approaches on prodrug based drug design. Pharmaceutical Chemistry Journal, 42(12):677–686.

Rasheed, A., Kumar, C. K. A., Mishra, A. 2011. Synthesis, hydrolysis studies and phamacodynamic profiles of amide prodrugs of dexibuprofen with amino acids. Journal of Enzyme Inhibition and Medicinal Chemistry, 26(5):688–695.

Rasheed, A., Lathika, G., Raju, Y. P., Mansoor, K. P., Azeeem, A. K., Balan, N. 2016. Synthesis and pharmacological evaluation of mutual prodrugs of aceclofenac with quercetin, vanillin and l-tryptophan as gastrosparing NSAIDS. Medicinal Chemistry Research, 25(1):70–82.

Rebecca, S. Y., Wong 2019. Role of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Cancer Prevention and Cancer Promotion. Advances in pharmacological and pharmaceutical sciences, pages 1–10.

Schrödinger 2015. About Induced Fit, USA: Induced fit.

Shati, A. A., Elsaid, F. G., Hafez, E. E. 2011. Biochemical and molecular aspects of aluminium chloride-induced neurotoxicity in mice and the protective role of Crocus sativus L. extraction and honey syrup. Neuroscience, 175:66–74.

Silverstein, R. M., Webster, F. X. 1998. Spectrophotometric identification of organic compounds. pages 1–502, New York. John Wiley and Sons Inc.

Taïr, K., Kharoubi, O., Taïr, O. A., Hellal, N., Benyettou, I., Aoues, A. 2016. Aluminium-induced acute neurotoxicity in rats: Treatment with aqueous extract of Arthrophytum (Hammadascoparia). Journal of Acute Disease, 5(6):470–482.

Vorhees, C. V., Williams, M. T. 2006. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nature Protocols, 1(2):848–858.

Španić, E., Horvat, L. L., Hof, P. R., Šimić, G. 2019. Role of Microglial Cells in Alzheimer’s Disease Tau Propagation. Frontiers in Aging Neuroscience, 11:271–271.

Weydert, C. J., Cullen, J. J. 2010. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nature Protocols, 5(1):51–66.

Wolmarans, D. W., Stein, D. J., Harvey, B. H. 2016. Of mice and marbles: Novel perspectives on burying behavior as a screening test for psychiatric illness. Cognitive, Affective, & Behavioral Neuroscience, 16(3):551–560.

Zhang, X., Liu, X., Gong, T., Sun, X., Zhang, Z. R. 2012. In vitro and in vivo investigation of dexibuprofen derivatives for CNS delivery. Acta Pharmacologica Sinica, 33(2):279–288.